We are live on ! Find out more
WP

Waycross Partners Portfolio holdings

AUM $1.05B
1-Year Est. Return 20.92%
This Fund
S&P 500
This Quarter Est. Return
+10.5%
1 Year Est. Return
+20.92%
3 Year Est. Return
+78.91%
5 Year Est. Return
+114.23%
10 Year Est. Return
–
AUM
$461M
AUM Growth
+$117M
Cap. Flow
+$81.3M
Cap. Flow %
17.64%
Top 10 Hldgs %
41.02%
Holding
99
New
12
Increased
35
Reduced
15
Closed
4

Top Buys

Rank Stock Value
1
TGT icon
Target
TGT
+$13.3M
2
HUM icon
Humana
HUM
+$12M
3
TMO icon
Thermo Fisher Scientific
TMO
+$10.7M
4
AAPL icon
Apple
AAPL
+$5.41M
5
MSFT icon
Microsoft
MSFT
+$4.78M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$9.98M
2
ADBE icon
Adobe
ADBE
+$6.4M
3
ELAN icon
Elanco Animal Health
ELAN
+$2.14M
4
CSL icon
Carlisle Companies
CSL
+$1.33M
5
MRVL icon
Marvell Technology
MRVL
+$1.32M

Sector Composition

Rank Sector Weight
1 Technology 26.06%
2 Healthcare 20.03%
3 Consumer Discretionary 15.74%
4 Financials 15%
5 Industrials 8.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
76
BioMarin Pharmaceuticals
BMRN
$11.5B
$607K 0.13%
7,000
– –
AMGN icon
77
Amgen
AMGN
$197B
$577K 0.13%
2,600
– –
MTB icon
78
M&T Bank
MTB
$36B
$563K 0.12%
4,550
+2,300
+102% +$278K
NKE icon
79
Nike
NKE
$64.1B
$519K 0.11%
4,700
– –
GPN icon
80
Global Payments
GPN
$22.5B
$517K 0.11%
5,250
+500
+11% +$51.4K
BNY
81
Bank of New York Mellon
BNY
$108B
$512K 0.11%
11,500
+4,000
+53% +$172K
SNOW icon
82
Snowflake
SNOW
$95.9B
$493K 0.11%
2,800
-300
-10% -$48.8K
STWD icon
83
Starwood Property Trust
STWD
$6.17B
$475K 0.1%
+24,500
New +$435K
CL icon
84
Colgate-Palmolive
CL
$73.2B
$462K 0.1%
6,000
– –
FISV
85
Fiserv Inc
FISV
$27.4B
$404K 0.09%
3,200
– –
KMI icon
86
Kinder Morgan
KMI
$72.9B
$344K 0.07%
20,000
+3,000
+18% +$50.9K
LULU icon
87
lululemon athletica
LULU
$13.3B
$341K 0.07%
+900
New +$332K
UBS icon
88
UBS Group
UBS
$170B
$334K 0.07%
+16,500
New +$332K
STT icon
89
State Street
STT
$50.1B
$329K 0.07%
+4,500
New +$324K
RTX icon
90
RTX Corp
RTX
$265B
$309K 0.07%
3,151
– –
BMY icon
91
Bristol-Myers Squibb
BMY
$124B
$291K 0.06%
4,557
– –
JNJ icon
92
Johnson & Johnson
JNJ
$601B
$281K 0.06%
1,700
– –
TFC icon
93
Truist Financial
TFC
$62.4B
$273K 0.06%
+9,000
New +$280K
NTRS icon
94
Northern Trust
NTRS
$34B
$256K 0.06%
+3,450
New +$265K
XOM icon
95
ExxonMobil
XOM
$617B
$224K 0.05%
2,090
– –
ELAN icon
96
Elanco Animal Health
ELAN
$12.8B
– –
-228,149
Closed -$2.14M
HAL icon
97
Halliburton
HAL
$29.8B
– –
-21,700
Closed -$687K
PFE icon
98
Pfizer
PFE
$142B
– –
-5,245
Closed -$214K
TEAM icon
99
Atlassian
TEAM
$24.5B
– –
-2,850
Closed -$488K
1 2 3
4

Similar funds

RC
Randolph Company Cincinnati, Ohio $1.05B AUM 35.91% 1-Year Est. Return
LPC
Long Pond Capital New York $1.05B AUM 16.49% 1-Year Est. Return
ANBT
American National Bank & Trust Wichita Falls, Texas $1.05B AUM 25.3% 1-Year Est. Return
HWCM
Hudson Way Capital Management Dallas, Texas $1.05B AUM 6.84% 1-Year Est. Return
AA
Apriem Advisors Irvine, California $1.05B AUM 22.09% 1-Year Est. Return
AAIM
Asset Advisors Investment Management Augusta, Georgia $1.05B AUM 12.32% 1-Year Est. Return
CIA
CCM Investment Advisers Columbia, South Carolina $1.04B AUM 40.82% 1-Year Est. Return
TPWA
TRUE Private Wealth Advisors Salem, Oregon $1.05B AUM 19.14% 1-Year Est. Return

Waycross Partners's Q2 2023 Portfolio in Review

As of Q2 2023, Waycross Partners held 99 positions worth $461M, up 34% from $344M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Waycross Partners deployed $81.3M of net new capital in Q2 2023, opening 12 new positions and adding to 35 existing holdings. Its largest new stake was Thermo Fisher Scientific: 19,775 shares worth $10.3M.

By sector, the portfolio is most concentrated in Technology at 26% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was Eli Lilly, an estimated $9.98M trimmed.

  • Waycross Partners's largest Q2 2023 buy was Thermo Fisher Scientific: 19,775 shares worth $10.3M.
  • Waycross Partners added most to Target in Q2 2023, an estimated $13.3M increase.
  • Waycross Partners's biggest Q2 2023 reduction was Eli Lilly, cutting an estimated $9.98M.
  • Waycross Partners fully exited Elanco Animal Health in Q2 2023, selling an estimated $2.14M.
  • Waycross Partners's ten largest holdings make up 41% of its $461M portfolio in Q2 2023.
  • Waycross Partners opened 12 new positions and closed 4 in Q2 2023.
  • Waycross Partners's portfolio value rose 34% quarter-over-quarter to $461M.

Based on Waycross Partners's 13F filing for Q2 2023, filed 26 Jul 2023.